Research employing mouse xenograft shown that olaparib was successful to potentiate the antitumor outcome of irinotecan. In summary, olaparib exhibits a synergistic influence in colon cancer cells in combination with SN-38 or irinotecan, potentiated by the Rad51-mediated HR pathway, no matter the Mre11-mediated failure with the MRN advanced. These success https://wst-822109.activosblog.com/17177069/stm2457-no-further-a-mystery